Accessibility Menu
Mbx Biosciences Stock Quote

Mbx Biosciences (NASDAQ: MBX)

$17.96
(3.0%)
+0.52
Price as of October 28, 2025, 4:00 p.m. ET

KEY DATA POINTS

Current Price
$17.96
Daily Change
(3.0%) +$0.52
Day's Range
$16.95 - $18.74
Previous Close
$17.96
Open
$17.43
Beta
1.80
Volume
827,586
Average Volume
1,205,105
Market Cap
803.1M
Market Cap / Employee
$17.96M
52wk Range
$4.81 - $27.50
Revenue
-
Gross Margin
-
Dividend Yield
N/A
EPS
-$2.31
CAPs Rating
-
Industry
Pharmaceuticals

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Mbx Biosciences Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
MBX-9.57%N/AN/A-24%
S&P+18.33%+108.18%+15.79%+22%

Mbx Biosciences Company Info

MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of peptide therapies for the treatment of endocrine and metabolic disorders. Its product candidates and programs include MBX 2109, MBX 1416, and obesity portfolio. The company was founded by Peter Kent Hawryluk and Richard D. DiMarchi in August 2018 and is headquartered in Carmel, IN.

News & Analysis

Financial Health

General

Q2 2025YOY Change
Revenue$0.00M0.0%
Gross Profit-$0.10M-58.7%
Market Cap$381.37M0.0%
Market Cap / Employee$8.87M0.0%
Employees430.0%
Net Income-$19.41M-22.4%
EBITDA-$21.71M-30.8%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$39.78M218.2%
Inventory00.0%

Liabilities

Q2 2025YOY Change
Long Term Debt$0.53M148.6%
Short Term Debt$0.14M-14.8%

Ratios

Q2 2025YOY Change
Return On Assets-52.32%0.0%
Return On Invested Capital-42.45%0.0%

Cash Flow

Q2 2025YOY Change
Free Cash Flow-$18.14M-32.2%
Operating Free Cash Flow-$17.43M-31.4%

Valuation

MetricQ3 2024Q4 2024Q1 2025Q2 2025YoY Change
Price to Book-8.452.270.961.62-
Price to Tangible Book Value-8.452.270.961.62-
Enterprise Value to EBITDA-30.25-19.08-0.22-7.25-
Return on Equity-48.2%-56.3%-
Total Debt$0.28M$0.21M$0.15M$0.67M77.81%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.